This analysis examines the current position and future outlook for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Serono’s performance against key rivals in the biotechnology sector
Understand the driving factors behind Serono’s forecast 8.4% CAGR between 2004 and 2010
Assess the effectiveness of Serono’s strategy of targeting niche therapeutic areas
